CJC-1295 is a synthetic version of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary telling it to release growth hormone. Natural GHRH is broken down in minutes. CJC-1295 was engineered to last days. Most people take it to push growth hormone and IGF-1 higher than their current baseline, with the goal of faster recovery, better body composition, deeper sleep, and improved skin and connective tissue quality as they age.
There are two versions sold under the same name and they behave completely differently. CJC-1295 with DAC binds to albumin in your blood and stays active for about a week, giving a sustained background lift in GH and IGF-1. CJC-1295 without DAC (also called Mod GRF 1-29) clears in about 30 minutes and only produces a single GH pulse per injection. The DAC version is what most people mean when they say "CJC-1295." The no-DAC version is what's almost always stacked with ipamorelin, where it mimics a natural GHRH pulse rather than creating constant background stimulation. Which one you take matters more than the dose.
Deep-dive
GHRH is the upstream signal in the GH axis. The hypothalamus releases it in pulses, it hits GHRH receptors on somatotroph cells in the anterior pituitary, those cells release a burst of growth hormone, the GH travels to the liver and other tissues where it triggers IGF-1 production, and IGF-1 mediates most of the downstream anabolic and metabolic effects (muscle protein synthesis, lipolysis, collagen synthesis, glucose handling). Natural GHRH has a plasma half-life of about 7 minutes because the enzyme DPP-4 chops it up almost immediately. This is why GHRH itself was never a viable therapy, you'd have to infuse it continuously.
CJC-1295 is a modified GHRH (1-29) fragment with four amino acid substitutions that protect it from DPP-4 degradation. The "DAC" (Drug Affinity Complex) version adds a maleimidopropionyl group at the C-terminus that covalently bonds to a cysteine residue on albumin once injected. Albumin is the most abundant protein in blood and has a half-life of about 19 days, so the peptide essentially hitches a ride and stays in circulation. The Teichman 2006 trial in healthy adults found a half-life of 5.8-8.1 days, GH elevated 2-10 fold for 6+ days, and IGF-1 elevated 1.5-3 fold for 9-11 days after a single subcutaneous dose. With weekly dosing, IGF-1 stayed above baseline for 28 days, indicating a cumulative effect.
The pulsatility question. This is the most important conceptual point and the one that splits opinion on which version to use. GH is normally released in pulses, mostly at night, with very low trough levels between pulses. The pulse-vs-trough pattern is thought to matter for downstream signalling, somatostatin (the brake on GH) cycles in opposition to GHRH, and chronically flat-high GH (as in acromegaly or exogenous HGH) drives different and worse outcomes than pulsatile GH at the same average level. The concern with CJC-1295 DAC is that continuous GHRH stimulation collapses the pulse pattern into a flat elevation. Ionescu and Frohman's 2006 follow-up addressed this directly and found that GH pulsatility was preserved after CJC-1295 administration, the frequency and amplitude of pulses didn't change, but trough levels rose 7.5-fold. So the pattern shifts from "pulses on top of near-zero baseline" to "pulses on top of a raised baseline." That's less physiological than no-DAC + ipamorelin (which mimics a clean GHRH pulse) but more physiological than exogenous HGH (which is flat and shuts down endogenous production entirely).
Why people stack it with ipamorelin. Ipamorelin is a ghrelin receptor agonist, a separate pathway from GHRH. The two receptors are on the same pituitary cells but work synergistically, hitting both simultaneously produces a bigger GH pulse than either alone. The standard stack uses no-DAC CJC-1295 (short half-life) + ipamorelin together to recreate a strong, clean nighttime GH pulse without raising daytime trough levels. This is the cleaner protocol if you're trying to mimic natural physiology. The DAC version + ipamorelin is also common but the rationale is weaker, the DAC version is already producing continuous GHRH stimulation so adding more upstream drive is partly redundant.
What it actually does in humans. The pharmacokinetic data is solid. The clinical outcome data, in humans, on body composition and other endpoints, is essentially absent. The Phase 2 trial for HIV-related lipodystrophy was halted in 2007 after a participant died (deemed unrelated to the drug, but commercial development stopped). What we know about effects on muscle, fat, and recovery comes from extrapolating from HGH and IGF-1 biology, animal studies (e.g. the GHRH-knockout mouse normalisation study), and a large body of consistent user reports. The honest framing is: the GH and IGF-1 elevations are real and measurable, the downstream effects on body composition, sleep, and skin are extrapolated and anecdotal rather than RCT-proven in non-deficient adults.
Anecdotal pattern. Across forums and clinic reports, the most consistently reported effects are deeper sleep within the first 1-2 weeks (often the first thing people notice), improved skin elasticity and hydration over 2-3 months, faster recovery from training and minor injuries, gradual reduction in visceral fat, and improved nail and hair quality. Less consistent: meaningful muscle gain (most people don't gain noticeable mass without also training and eating for it), strength changes, libido changes. Common complaints: facial flushing in the first 30-60 minutes after injection (the vasodilatory effect of GHRH, usually fades after the first few doses), water retention and mild tingling in hands and feet (carpal tunnel-type symptoms at higher doses), occasional headaches, and lethargy if dosed too high. The flushing is a useful crude marker that the product is bioactive.
Women. GH and IGF-1 biology is broadly similar between sexes but women have higher baseline GH pulse amplitude and a more pronounced response to oestrogen, which upregulates GH secretion. There's no dedicated trial of CJC-1295 in women, the Teichman healthy-adult study enrolled both sexes without breaking out results. Practically, women in clinical settings tend to use the same dose range as men (sometimes the lower end) and report similar effects. The skin and body composition effects appear to be at least as good in women, consistent with the broader GH/IGF-1 literature. Skip it in pregnancy and breastfeeding, no safety data and the GH/IGF-1 axis is tightly regulated during these periods. Perimenopausal and postmenopausal women may notice more benefit because endogenous GH output drops with declining oestrogen.
Older adults. GH output declines roughly 14% per decade after age 30. CJC-1295 is most often used in adults over 35-40 specifically to push GH and IGF-1 back toward younger ranges. The mechanism is sound but the long-term safety data in this group is the weakest part of the picture, see the risks section.
Limitations of the evidence. There is one well-controlled human pharmacokinetic study (Teichman 2006, n=21 in part 1, n=10 in part 2), one mechanism study on pulsatility (Ionescu 2006), and a Phase 2 trial that was halted. There are no published trials measuring body composition, lean mass, fat mass, sleep quality, or skin metrics as endpoints in healthy adults on CJC-1295. Everything beyond GH and IGF-1 elevation is inferred. Most peptide manufacturers operate in a grey market, product purity and identity vary widely, and the FDA placed CJC-1295 on the 503A Category 2 list in 2023 citing immunogenicity and impurity concerns. As of 2026, regulatory status is in flux pending PCAC review, but the practical reality is that this is a research chemical sold for off-label human use.
Dosage:
- CJC-1295 with DAC: 1-2 mg subcutaneous, once weekly. Some protocols split this into 2x 1 mg per week. Higher doses don't produce more GH (the receptor saturates) and increase side effects. Most clinical experience clusters at 2 mg/week
- CJC-1295 without DAC (Mod GRF 1-29): 100-300 mcg subcutaneous, 1-2x daily. Most commonly dosed at night before bed to align with natural GH pulse, or post-workout. If splitting, morning and pre-bed
- CJC-1295 (no-DAC) + ipamorelin stack: 100 mcg of each, taken together, 1-3x daily. The pre-bed dose is the most important if you only do one. Pre-workout is the next priority. Wait 30-60 minutes before eating, food (especially carbs and protein) blunts the GH pulse via insulin and IGF-1 feedback
- Timing: GH pulses are most physiologic at night during deep sleep. Inject 30+ minutes before food and ideally at the same time daily for the DAC version, or pre-bed for the no-DAC version. Avoid taking it within 2 hours of a meal, the GH response is significantly blunted by elevated insulin or amino acids
- Cycling: Most protocols run 3-6 months on, then 1-2 months off. The off period lets receptor sensitivity reset and gives you a window to recheck IGF-1, fasting glucose, and HbA1c. Indefinite continuous use is not well-studied
- Women: Start at the lower end of the dose range (e.g. 1 mg/week DAC or 100 mcg no-DAC) and assess response over 4-6 weeks. No dedicated female dosing trials, but clinical practice and reports support similar dosing to men
- Reconstitution: Comes as lyophilised powder, reconstitute with bacteriostatic water, store refrigerated, and use within 30 days. Subcutaneous injection into abdominal fat or thigh with an insulin syringe
Here's what you can expect:
The first thing most people notice, usually within the first 1-2 weeks, is deeper and more restorative sleep. This is one of the most consistent reports. Skin changes (firmness, hydration, fewer fine lines) come gradually over 2-3 months, similar to GHK-Cu but driven by IGF-1 rather than direct fibroblast signalling. Recovery from training feels faster within the first month. Body composition changes (modest visceral fat reduction, mild lean mass preservation or gain) build over 3-6 months and require that you're also training and eating reasonably, this is not a body-recomposition compound on its own.
Facial flushing in the 30-60 minutes after injection is normal and usually fades within the first 1-2 weeks. Mild water retention and tingling in the hands or feet at higher doses are signals to dial back. If you're not noticing anything after 6-8 weeks at a standard dose, the product is likely under-dosed or degraded, this is common with grey-market sources.
Side effects & risks:
- Injection site reactions are the most common, redness, itching, mild swelling, occasional bruising. Rotate injection sites
- Facial flushing and warmth in the first 30-60 minutes after injection. This is the vasodilatory effect of GHRH receptor activation and is harmless. Usually fades after the first few doses
- Headache, lethargy, and "foggy" feeling at higher doses or if dosed too late in the day. Pull the dose back
- Water retention and tingling (paraesthesia) in hands and feet are early signs of mild carpal tunnel-type symptoms from elevated GH. Reversible. Reduce dose if persistent
- Insulin resistance and elevated fasting glucose. This is the most important metabolic concern. GH is counter-regulatory to insulin, sustained elevation pushes fasting glucose and HbA1c up. Modest in most people but meaningful if you already have prediabetes or metabolic syndrome. Recheck glucose markers at 3 months
- Receptor desensitisation with continuous long-term use, which is why most protocols cycle
- Active or recent cancer, avoid. IGF-1 is mitogenic. Elevated IGF-1 levels are epidemiologically associated with increased risk of several cancers (colorectal, prostate, breast) over long timescales. The absolute risk increase from short cycles in healthy adults is unclear but the biology is real. Hard contraindication if you have a current or recent cancer diagnosis
- Diabetic retinopathy can worsen with elevated GH/IGF-1. Avoid if you have any active diabetic eye disease
- Pregnancy and breastfeeding: avoid
- Pituitary tumour or unexplained hyperprolactinaemia: avoid until worked up
- Sleep apnoea can worsen with GH elevation due to soft tissue changes, monitor if you have it
- Long-term safety data is essentially absent. The longest controlled human trial ran 49 days. Beyond 3-6 month cycles, what you're doing is inferring safety from related GH literature
- Grey-market sourcing. Most CJC-1295 sold online is labelled "research use only" and is not made under pharmaceutical conditions. Identity, purity, and dose accuracy vary widely. Third-party tested sources are worth the premium
- FDA regulatory status: as of 2026 CJC-1295 sits on the 503A Category 2 list, meaning US compounding pharmacies cannot legally produce it for patient use pending PCAC review. WADA prohibits it in competition
Blood markers
IGF-1, baseline and at 6-8 weeks. This is the most useful single marker for whether the compound is working and at what intensity. Aim to land in the upper end of the age-adjusted reference range, not above it.
Fasting glucose and HbA1c, baseline and at 3 months. The metabolic cost of sustained GH elevation. If fasting glucose creeps above 100 mg/dL or HbA1c above 5.7%, reduce dose or stop.
Fasting insulin and HOMA-IR, baseline if you want a more sensitive read on insulin resistance than glucose alone. Recheck at 3 months.
Full lipid panel, baseline. GH and IGF-1 can shift lipid markers in either direction. Recheck at 3 months.
TSH, free T4, free T3, baseline. GH can suppress TSH and shift T4 to T3 conversion. Worth knowing if you have any thyroid history.
Prolactin and cortisol, baseline. Mostly to rule out a pituitary issue before pushing the axis, CJC-1295 itself doesn't meaningfully affect these.
For most people the practical minimum is IGF-1 + fasting glucose + HbA1c at baseline and at 3 months. Anything beyond that is for completeness or troubleshooting.
Sold as a research chemical, not approved for human use in the US, EU, or most jurisdictions.
Made with Bullet